1-877-7RADPAD     info@radpad.com

Tag: Interventional-cardiology

radiation-protection-products
RADPAD® Radiation Products Protect Healthcare Providers and Patients

RADPAD® Radiation Products Protect Healthcare Providers and Patients

Posted on March 18, 2019 by in Uncategorized with no comments

RADPAD® Absorbs Scatter Radiation

RADPAD® Radiation Protection Shields are used by physicians and cath lab personnel during fluoro-guided procedures to protect them from the harmful effects of ionizing x-radiation. Placed on the patient in front of the operator, RADPAD® works by absorbing scatter radiation coming from the patient and creating a “shade zone” for the cath lab team to work in during interventional procedures. All RADPAD® Radiation Protection Products are non-lead and PVC-free products. They are procedure specific and designed for single use.

RADPAD-radiation-protection
radpad-radiation-protection
radpad-in-use

Physician Protection

Sterile, disposable RADPAD® Radiation Protection Products are placed directly on the patient to protect the operator and cath lab personnel during fluoro-guided procedures from harmful scatter radiation. They are backed by 30 clinical studies and proven in thousands of hospitals on a daily basis worldwide

RADPAD® 5000 series products are comprised of several procedure-specific radiation protection shields designed to provide maximum protection to the operator and cath lab personnel during fluoro-guided procedures

RADPAD® 7000 series are comprised of several procedures specific sterile drape + RADPAD® Radiation Protection Shields, designed to protect operators and cath lab personnel during fluoro-guided procedures

RADPAD® 9000 series of Personal Protection Products are comprised of products worn by the operator and cath lab personnel to for additional protection during fluoro or CT guided procedures. These products include:

  • RADPAD® No Brainer®  is an attenuation material-lined scrub cap worn by the cath lab personnel to protect their brain from scatter radiation during fluoro-guided procedures
  • RADPAD® Thyroid Shield w/ Cover is a RADPAD® thyroid shield worn by the cath lab personnel to protect thyroid glands during fluoro-guided procedures
  • RADPAD® Radiation Protection Sleeve is a full arm-length cover worn the operator during CT guided procedures

Additional Products

RADPAD® Table Skirts w/ Anchor are table skirts that anchor to the table in the cath lab to block scatter radiation coming from below the table

 

Patient Protection

RADPAD® Specialty Shields: Shields of various shapes and sizes used to protect the patient during fluoro guided, interventional radiology, electrophysiology, and cardiac cath examinations

RADPAD® Patient Protection Pads: Pads used underneath the lower or upper body during fluoro-guided procedures

RADPAD® Body Guard Sets: Wraps fitted for adults, children, and infants used to protect the brain, thyroid, upper and lower body during CT examinations

 

Testimony of Clinical Need for Radiation Protection

“72 million CT scans are performed annually in the United States, which is about one scan for every four people in the country…which could account for roughly 29,000 future cancer cases each year!”¹

“In 2013, a scientific consensus was reached that even just one CT scan in childhood is linked to the risk of developing future cancers.”²

“Even 15 or more years after the first exposure to ionizing radiation from CT scan, cancer risks remain elevated by 24%.”³

Sterile, disposable RADPAD® Radiation Protection Products are placed directly on the patient to protect the operator and cath lab personnel during fluoro-guided procedures from harmful scatter radiation. They are backed by 30 clinical studies and proven in thousands of hospitals on a daily basis worldwide.


Contact Us or send inquiries to info@radpad.com for a free No Brainer™ surgical cap sample.

 

The original article appeared on https://www.medalliancegroup.com/product/radpad/.
RADPAD-scatter-radiation-protectio
Radiation Exposure May Increase Alzheimer’s Risk– How Can You Stay Protected?

Radiation Exposure May Increase Alzheimer’s Risk– How Can You Stay Protected?

Posted on June 11, 2018 by in Uncategorized with no comments

June is National Alzheimer’s & Brain Awareness Month. More than five million Americans are living with Alzheimer’s, and deaths caused by the disease have increased by 89% since 20001. Clinical studies have shown that exposure to low and high doses of ionizing radiation can be a risk factor in developing Alzheimer’s2.

The RADPAD® from Worldwide Innovations & Technologies, Inc. is a sterile shield comprised of specially developed radiation attenuating material, clinically-proven to protect both physicians and patients from the harmful effects of scatter radiation during fluoro-guided procedures and CT scans. The RADPAD® works by absorbing scatter radiation that is projected from the patient, as well as creates a “shade zone” for cath lab personnel so they are protected during interventional procedures. (Insert the picture showing the “shade zone” by this paragraph)

The RADPAD® No Brainer®, an attenuation material-lined scrub cap, is worn by physicians in the cath lab to protect the brain from scatter radiation during fluoro-guided procedures.

The No Brainer

The No Brainer

The RADPAD® Body Guard Sets, which are wraps fitted for adults, children, and infants, contain a separate wrap to protect the patient’s brain during CT examinations.

The RADPAD® is also important for protecting both physicians and patients from the increased risk of cancer due to exposure to radiation. In a clinical study, results showed that cancer risks from radiation remain elevated by 24% even after 15+ years of the first exposure3.

For more information on the RADPAD®, contact your local MED Alliance Group Sales Representative, call 888-891-1200 or email us.

 

1 “2017 Alzheimer’s Disease Facts and Figures.” alz.org®, 2017, http://www.alz.org/facts/overview.asp.

2 Begum, Nasrin; Mori, Masahiko; Vares, Guillaume; Wang, Bing. “Does ionizing radiation influence Alzheimer’s disease risk?” US National Library of Medicine National Institutes of Health. vol. 53., no. 6, 2012, pp. 815-822.

3 Mathews JD, Forsythe AV, Brady Z, et al, Cancer risk in 680,000 people exposed to computer tomography scan in childhood or adolescence data linkage study of 11 million Australians. BMJ. 2013; 346:f2360.


CONTACT US

Send inquiries to info@radpad.com for a free No Brainer™ sample. The No Brainer™ blocks up to 95% of radiation exposure to the brain. Lightweight, adjustable protection for all O.R. suite and fluoro lab personnel during interventional procedures.

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730 or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131
Unknown
interventional-radiology-5511-in-use3-thumb
RADPAD® Safety News:  Radiation Exposure in Cath Lab Depends on Shield Placement

RADPAD® Safety News: Radiation Exposure in Cath Lab Depends on Shield Placement

Posted on February 19, 2018 by in Safety with no comments

MedPage Today and the American Heart Association collaborated on an insightful article explaining the importance of shield placement in the reduction of scatter radiation exposure:

 

MEDPAGE TODAY ®

Cardiology

Radiation Exposure in Cath Lab Depends on Shield Placement

by Chris Kaiser

Cardiology Editor, MedPage Today October 17, 2011

 

This article is a collaboration between MedPage Today® and:

Screen Shot 2018-02-19 at 2.07.31 PMlife is why

Interventional cardiologists are at greatest risk of scatter radiation exposure compared with other personnel in the cath lab, but their risk can be significantly reduced with the optimal placement of radiation shielding, researchers found.

A ceiling-mounted upper body shield protected best from scatter radiation when it was positioned tight to the patient’s body and just toward the head from the femoral access point, reported Kenneth A. Fetterly, PhD, from the Mayo Clinic in Rochester, Minn., and colleagues.

However, a difference of 5 cm away from the patient’s body and 20 cm closer to the x­ ray tube resulted in a fourfold reduction in protection, according to the study in Oct. 25 Journal of the American College of Cardiology: Cardiovascular Interventions.

“That the most advantageous shield positioning can have a greater than fourfold relative reduction in scatter radiation exposure, supports its use even when inconvenient, and suggests that learning to coordinate multiple shields should be among the fundamental principles taught in every interventional cardiology training program,” wrote Lloyd W. Klein, MD, and Justin Maroney, MD, from Advocate Illinois Masonic Medical Center in Chicago, in an accompanying editorial.

Klein and Maroney noted that the design of the interventional suite has remained stagnant over the past few decades even as innovations in techniques and devices have soared. And because optimal placement of shielding “continues to be operator­ dependent,” it requires a deliberate effort on the part of cath lab personnel to place shield s.

To determine how best to protect against scatter radiation, which occurs when the primary x-ray beam interacts with patient tissue and changes direction, investigators tested four different shielding models individually and in com binat ion:

 

  • A ceiling-mounted upper body shield

 

  • A table side rail-mounted lower body shield

 

  • An accessory vertical shield that mounts as an upper extension of the lower body shield

 

  • A disposable radiation-absorbing pad

 

Researchers used anthropomorphic phantoms through which they directed the x-ray beam in a straight posterior-anterior posit ion.

They measured the scatter radiation from three common physician positions corresponding to standard right femoral art ery, right jugular vein, and left anterior thoracic access point s.

Results showed that maximum protection was provided at the femoral artery access position compared with the other two access points.

When the ceiling-mounted upper body shield was moved away from the patient’s body by 5 cm, and moved more cephalad from the femoral access point by 20 cm, the protective benefit to the middle and upper body went from greater than 80% to less than 20%.

The accessory vertical extension to the lower body shield provided between 25% and 90% additional protection at heights in the range of 100 cm to 150 cm. The disposable pad also provided extra upper body protection, in the range of 55% to 70%.

Researchers found that the combined use of the table apron with vertical extension and the upper body shield resulted in “at least 80% protection at all elevations and 90% protection for elevations below 150 cm” at the femoral access point.

Regarding protection from the right jugular vein and left anterior thoracic access points, testing showed that the lower body shield provided better than 90% reduction in scatter exposure, but no upper body protection, while the disposable pad provided lower body protection and only modest upper body protection (between 40% to 70%).

The upper body shield also interfered with the x-ray receptor and patient access when the right jugular vein access point was used, and it interfered with patient access from the anterior thoracic access point. Patient interference was common with the vertical extension as well.

“A major finding of this work is that the upper body protection provided by the ceiling­ mounted upper body shield is highly dependent on precise positioning,” researchers wrote.

“Note that conventional wisdom is that shields should be placed close to the source of radiation to maximize the size of the protective ‘radiation shadow’ of the shield. Properly positioning the upper body shield requires the opposite mindset,” Fetterly and colleagues said.

Klein and Maroney echoed this sentiment, saying the shield should be used “as one would use an umbrella in wind-driven rain: the closer to the operator’s body the more eff ect ive.”

Limitations of the study included the use of only the posterior-anterior projections, and the lack of an analysis of radiation scatter when involved with the treatment of abdominal and peripheral vessels.

 

The study authors and the editorialists reported relationships relevant to the contents of the study or editorial.

 Reviewed by Zalman S. Agus, MD Em er itus Professor

University of Pennsylvania School of Medicine and Dorothy Caputo, MA, RN , BC-ADM, CDE, Nurse Planner 

Primary Source

JACC: Cardiovascular Interventions

Source Reference: Fetterly, KA et al “Effective use of radiation shields to minimize operator dose during invasive cardiology procedures” J Am Coll Cardiol Intv 2011; 4: 1133-1139.

Secondary Source

JACC: Cardiovascular Interventions

Source Reference : Klein LW, et al “Optimizing operator protection by proper radiation shield positioning in the interventional cardiology suite” J Am Coll Cardiol Intv 2011;4:1140-1141.


CONTACT US

Send inquiries to info@radpad.com for a free No Brainer™ sample. The No Brainer™ blocks up to 95% of radiation exposure to the brain. Lightweight, adjustable protection for all O.R. suite and fluoro lab personnel during interventional procedures.

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730 or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131
Unknown

 

x-ray-radiation-protection-sleeve
Scatter Radiation is Unavoidable, Physician Protection is Not

Scatter Radiation is Unavoidable, Physician Protection is Not

Posted on November 27, 2017 by in Products, Safety with no comments

Protecting Hospital Staff During Fluoro-Guided Procedures

Radiation Therapy is a powerful tool in medicine, especially when used to treat cancer. Radiation works by killing and slowing the growth of cancer cells – but it can also damage healthy cells in the process, which can increase the risk of developing cancer in the future.

In 2017, approximately 80,000 new cases of brain tumors are expected to be diagnosed, with roughly 26,000 of those being malignant cases.^1 This depicts brain and other central nervous system cancer as the 10th leading cause of death in both men and women, and an estimated 16,700 individuals are expected to die from primary brain cancer this year. ^2

 

RADPAD® Radiation protection Products

While healthcare providers are diligent in their efforts to keep patients safe from scatter radiation, it is also important for providers to consider their safety when performing these procedures. Scatter radiation is secondary radiation that deflects from an object, most commonly the patient, during procedures, and can affect the healthcare provider’s brain in the process.

RADPAD® from Worldwide Innovations & Technologies is a full line of radiation protection products that are dedicated to protecting hospital staff during fluoro-guided procedures.

The No Brainer

The No Brainer®

The RADPAD® No Brainer® is an attenuation material-lined scrub cap worn by cath lab personnel that protects the brain from scatter radiation during fluoro-guided procedures.

 

x-ray-protection-thyroid-collar

Thyroid Collar

 

The RADPAD® is also available as a thyroid shield and a full-length protection sleeve to cover the neck and arms of the physician during these procedures.

 

RADPAD-table-skirt

Table Skirt with Anchor

The RADPAD® Table Skirt anchors to the table in the cath lab to block scatter radiation that flows from below the table, and the RADPAD® Specialty Shields create a shade zone where the physician can work from.

To learn more about how you can protect yourself and your patients with the RADPAD®, contact us:

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730 or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131

Unknown


1 http://www.abta.org/about-us/news/brain-tumor-statistics/?referrer=https://www.google.com/

2 http://www.cancer.net/cancer-types/brain-tumor/statistics

5511-used-in-cardiac-cath-procedure-thumb
RADPAD Presents: Cardiovascular Procedure Volume Growth Report

RADPAD Presents: Cardiovascular Procedure Volume Growth Report

Posted on September 19, 2017 by in Uncategorized with no comments

Here we present an article from MedMarket Diligence that provides information about the growth of cardiovascular procedure volume worldwide.

Based on their report described below, the volume of procedures is predicted to grow by an average of 3.7% per year from 2016 – 2022. The volume of corresponding surgeries and transcatheter interventions is forecast to expand to more than 18.73 million.

 

Cardiovascular procedure volume growth (interventional and surgical)

Cardiovascular surgical and interventional procedures are performed to treat conditions causing inadequate blood flow and supply of oxygen and nutrients to organs and tissues of the body. These conditions include the obstruction or deformation of arterial and venous pathways, distortion in the electrical conducting and pacing activity of the heart, and impaired pumping function of the heart muscle, or some combination of circulatory, cardiac rhythm, and myocardial disorders. Specifically, these procedures are:

  • Coronary artery bypass graft (CABG) surgery;
  • Coronary angioplasty and stenting;
  • Lower extremity arterial bypass surgery;
  • Percutaneous transluminal angioplasty (PTA) with and without bare metal and drug-eluting stenting;
  • Peripheral drug-coated balloon angioplasty;
  • Peripheral atherectomy;
  • Surgical and endovascular aortic aneurysm repair;
  • Vena cava filter placement
  • Endovenous ablation;
  • Mechanical venous thrombectomy;
  • Venous angioplasty and stenting;
  • Carotid endarterectomy;
  • Carotid artery stenting;
  • Cerebral thrombectomy;
  • Cerebral aneurysm and AVM surgical clipping;
  • Cerebral aneurysm and AVM coiling & flow diversion;
  • Left Atrial Appendage closure;
  • Heart valve repair and replacement surgery;
  • Transcatheter valve repair and replacement;
  • Congenital heart defect repair;
  • Percutaneous and surgical placement of temporary and permanent mechanical cardiac support devices;
  • Pacemaker implantation;
  • Implantable cardioverter defibrillator placement;
  • Cardiac resynchronization therapy device placement;
  • Standard SVT & VT ablation; and
  • Transcatheter AFib ablation

For 2016 to 2022, the total worldwide volume of these cardiovascular procedures is forecast to expand on average by 3.7% per year to over 18.73 million corresponding surgeries and transcatheter interventions in the year 2022. The largest absolute gains can be expected in peripheral arterial interventions (thanks to explosive expansion in utilization of drug-coated balloons in all market geographies), followed by coronary revascularization (supported by continued strong growth in Chinese and Indian PCI utilization) and endovascular venous interventions (driven by grossly underserved patient caseloads within the same Chinese and Indian market geography).

Venous indications are also expected to register the fastest (5.1%) relative procedural growth, followed by peripheral revascularization (with 4.0% average annual advances) and aortic aneurysm repair (projected to show a 3.6% average annual expansion).

Source: MedMarket Diligence, LLC; “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022,” (Report #C500).

Geographically, Asian-Pacific (APAC) market geography accounts for slightly larger share of the global CVD procedure volume than the U.S. (29.5% vs 29,3% of the total), followed by the largest Western European states (with 23.9%) and ROW geographies (with 17.3%). Because of the faster growth in all covered categories of CVD procedures, the share of APAC can be expected to increase to 33.5% of the total by the year 2022, mostly at the expense of the U.S. and Western Europe.

However, in relative per capita terms, covered APAC territories (e.g., China and India) are continuing to lag far behind developed Western states in utilization rates of therapeutic CVD interventions with roughly 1.57 procedures per million of population performed in 2015 for APAC region versus about 13.4 and 12.3 CVD interventions done per million of population in the U.S. and largest Western European countries.

Source: MedMarket Diligence, LLC; “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022,” (Report #C500).


Global Cardiovascular Procedures report #C500 details the current and projected surgical and interventional therapeutic procedures commonly used in the management of acute and chronic conditions affecting myocardium and vascular system.

Read the original article:

http://blog.mediligence.com/2017/02/13/cardiovascular-procedure-volume-growth-interventional-and-surgical/


CONTACT US

Send inquiries to info@radpad.com for a free No Brainer™ sample. The No Brainer™ blocks up to 95% of radiation exposure to the brain. Lightweight, adjustable protection for all O.R. suite and fluoro lab personnel during interventional procedures.

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730 or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131
Unknown

RADPAD Safety News: Low Doses of Radiation Could Harm Cardiovascular Health

Posted on August 31, 2017 by in Safety with no comments

It is known that populations exposed to ionizing radiation in medical or environmental settings have symptoms suggesting an increased risk of cardiovascular disease. However, this research study suggests that low exposure to doses of around 0.5 Gy (the equivalent of repeated CT scans) is associated with a significantly increased risk of cardiovascular damage, up to decades after exposure. This raises questions about the nature of long-term alterations in the heart’s vascular system caused by such doses.”

For more about this study read the article below, originally published by Diagnostic and Interventional Cardiology:


NEWS | RADIATION DOSE MANAGEMENT | JULY 17, 2017

Low Doses of Radiation Could Harm Cardiovascular Health

New study suggests dose of 0.5 Gy associated with significantly increased risk of cardiovascular damage as long as decades after exposure. 

Low Doses of Radiation Could Harm Cardiovascular Health

July 17, 2017 — Ionizing radiation, such as X-rays, has a harmful effect on the cardiovascular system even at doses equivalent to recurrent computed tomography (CT) imaging, a new study published in the International Journal of Radiation Biology suggests.

It is known that populations exposed to ionizing radiation in medical or environmental settings have symptoms suggesting an increased risk of cardiovascular disease. However, this research study suggests that low exposure to doses of around 0.5 Gy (the equivalent of repeated CT scans) is associated with a significantly increased risk of cardiovascular damage, up to decades after exposure. This raises questions about the nature of long-term alterations in the heart’s vascular system caused by such doses.

Soile Tapio, M.D., and Omid Azimzadeh, M.D., of Helmholtz Zentrum München, German Research Center for Environmental Health, and colleagues studied how human coronary artery endothelial cells respond to a relatively low radiation dose of 0.5 Gy and found several permanent alterations in the cells that had the potential to adversely affect their essential functions.

Endothelial cells, which form the inner layer of blood vessels, were found to produce reduced amounts of nitric oxide, an essential molecule in several physiological processes including vascular contraction. Previously, high-dose radiation (16 Gy) has been shown to persistently reduce levels of nitric oxide in the serum of mice, but this is the first study to indicate impaired nitric oxide signaling at much lower doses.

Cells damaged by low-dose radiation also produced increased amounts of reactive oxygen species (ROS), which are formed as a natural byproduct of normal oxygen metabolism and play an important role in cell signaling. Increased ROS can damage DNA and proteins.

In addition, exposed cardiac endothelial cells were found to have reduced capacity to degrade oxidized proteins and to be aging prematurely. Such harmful changes did not occur immediately (that is, within a day) but first began in the longer term (one to two weeks). As these cells do not divide rapidly in the body, this observed time in the cell culture would correspond to several years in the living organism.

All these molecular changes are indicative of long-term premature dysfunction and suggest a mechanistic explanation to the epidemiological data showing increased risk of cardiovascular disease after low-dose radiation exposure, the authors concluded.

 


CONTACT US

Send inquiries to info@radpad.com for a free No Brainer™ sample. The No Brainer™ blocks up to 95% of radiation exposure to the brain. Lightweight, adjustable protection for all O.R. suite and fluoro lab personnel during interventional procedures.

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730 or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131
Unknown
9100-in-use-thumb
RADPAD Interventional Cardiology News: the EARLY TAVR Trial

RADPAD Interventional Cardiology News: the EARLY TAVR Trial

Posted on July 21, 2017 by in Procedures with no comments

The following article from Diagnostic and Interventional Cardiology  offers interesting news about the EARLY TAVR trial, and insights from Philippe Genereux, M.D., interventional cardiologist and the trial’s lead investigator.

The EARLY TAVR trial’s purpose is to assess any health benefit from replacing the aortic valve through a minimally invasive, catheter-based procedure prior to patients showing symptoms, as opposed to the standard of care of observing patients until symptoms develop.

 

FEATURE | HEART VALVE TECHNOLOGY | JULY 14, 2017

First Patient in World Enrolled in Study Evaluating TAVR for Asymptomatic Severe Aortic Stenosis

Morristown Medical Center randomizes first patient in the EARLY TAVR trial, which may change treatment paradigm to save heart function, prevent deterioration

Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial

July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the world to the EARLY TAVR (Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis) trial.

Philippe Genereux, M.D., an interventional cardiologist and co-director of the Structural Heart Program at the Gagnon Cardiovascular Institute at Morristown Medical Center, serves as the trial’s principal (lead) investigator. The study is a U.S. Food and Drug Administration approved inventigational device exemption (IDE) trial.

Traditionally, patients with severe aortic stenosis (AS)—a narrowing of the aortic valve in the heart that keeps it from opening fully—who do not yet have symptoms (asymptomatic), are regularly followed and monitored by their cardiologist, and treatment is not initiated until they become symptomatic. However, many elderly patients with asymptomatic severe AS can develop irreversible heart damage or even die while waiting for symptoms to appear. The EARLY TAVR trial will evaluate whether there is benefit from replacing the aortic valve via a minimally invasive, catheter-based procedure (called a transcatheter aortic valve replacement) before patients develop symptoms (shortness of breath, dizziness, fainting, or angina) as compared to the standard of care of watching the patient until symptoms develop.

“The EARLY TAVR trial is an incredibly important trial for the more than 2.5 million people who suffer from aortic stenosis because it may provide an answer to the frequent dilemma cardiologists face about how they should treat severe aortic stenosis, even though patients have no symptoms,” Genereux explained. “The progression of aortic stenosis is unpredictable, and there may be a price to pay for waiting to treat—the goal of early intervention with valve replacement is to preserve the heart’s function, prevent further heart deterioration, and in some case, death.”

“As a nationally recognized leader in cardiology and cardiovascular surgery, Atlantic Health System is committed to both prolonging and improving the quality of life for patients with heart disease,” said Linda D. Gillam, M.D., MPH, The Dorothy and Lloyd Huck Chair of Cardiovascular Medicine at Morristown Medical Center/Atlantic Health System. “Our participation in clinical trials, like EARLY TAVR, not only ensures our patients have access to new treatments before they are approved or available to the general public, but helps our clinicians remain on the cutting edge of medicine with access to the latest medications, devices, and technology.”

 

About the EARLY TAVR Trial

Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis (EARLY TAVR) is a randomized, controlled, multi-center clinical trial study. Patients aged 65 and older diagnosed with asymptomatic, severe aortic stenosis will be randomized to receive a transcatheter aortic valve replacement (TAVR) with the Edwards Sapien 3 heart valve, or standard of care clinical surveillance. The study will enroll 1,000 patients in 65 cardiovascular centers.

Patients will be randomized (TAVR or surveillance) based on their ability to perform a treadmill stress test, as well as other factors. Those patients with a positive treadmill stress test or who do not meet other factors for randomization may be followed in a registry for data collection on subsequent treatment and mortality, as applicable.

The EARLY TAVR trial is sponsored by Edwards Lifesciences. According to Edwards Lifesciences, global transcatheter heart valve therapy (THVT) sales rose 29 percent to $432 million in the past year. In the United States, sales grew by 38 percent. Edwards said cardiac surgeons and interventional cardiologists are now implanting the company’s Sapien 3 TAVR devices at more than 500 hospitals in the U.S.

For more information: www.atlantichealth.org/valveresearch

CONTACT US

Send inquiries to info@radpad.com for a free No Brainer™ sample. The No Brainer™ blocks up to 95% of radiation exposure to the brain. Lightweight, adjustable protection for all O.R. suite and fluoro lab personnel during interventional procedures.

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730 or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131
Unknown

 

RADPAD-scatter-radiation-protectio
RADPAD Glossary of Some Common Interventional Techniques

RADPAD Glossary of Some Common Interventional Techniques

Posted on April 21, 2017 by in Uncategorized with no comments

5511-used-in-abdominal-procedure-thumb

Radiology is the branch of medical science that has seen a major boost in the past few years. With more and more doctors learning interventional techniques for radiology, it has become important that you get familiar with some of the glossary terms related to this technology.

Central Venous Access

This is one method that is used to insert nutrients or blood in the blood vessels of the patient. The needle is inserted just beneath the skin and also used to provide medication of any kind to the patients.

Bleeding internally

Unlike in the past, interventional radiologists can easily pinpoint the area of internal bleeding with angioplasty. This has helped a lot in the operations that need to be performed after a person has sustained a severe accident. When the point of bleeding is discovered, the required blood clotting substance, gel, foam or tiny coils can be inserted with the help of a thin catheter that stop the bleeding.

Balloon Angioplasty

One of the most effective methods to open up clogged arteries in the legs, brains, arms, kidneys or anywhere in the body is balloon angioplasty. A very small balloon is inserted into the vessel and inflated to open it.

Biliary Drainage and Stenting

Excess bile in the liver can cause problems; the biliary drainage method is used to extract it. A stent is a small mesh tube that is used to open up blocked ducts and allow the bile to drain out.

Angiography

This is one of the superior X-ray exams that help in seeking out blockages and other blood vessel problems in the body. A catheter and a contrast agent (X-ray dye) are used to ensure the visibility of the artery.

Arteriovenous Malformations (AVM)

One of the biggest threats that can lead to internal bleeding and take lives is blood vessel abnormality. It can occur anywhere in the body. For this reason, arteriovenous malformations need to be treated properly. Interventional radiologists can treat this problem by inserting a catheter into the site of the bleeding.

Embolization

This is the process through which the clotting agent is delivered directly to the bleeding area in cases like an aneurysm or a fibroid tumor in the uterus. The clotting agents are the coils, plastic particles, gels, foams, and other materials.

High Blood Pressure

The problem of renal hypertension occurs due to the narrowing of the arteries in the kidneys. This problem leads to an increase in blood pressure. It can be easily treated with angioplasty.

Gastrostomy Tube

This is the tube that is inserted into the stomach of patients who are unable eat food usings their mouths.

Chemoembolization

Cancer is becoming curable, and the cancers of the endocrine system and the liver can be treated with this method. In this method of Chemoembolization, cancer-fighting agents are directly delivered to the site of the tumor of the cancer.

Needle Biopsy 

This is a great alternative to a surgical biopsy. The needle biopsy is used as a diagnostic test for breast, lung and other cancers.


Worldwide Innovations & Technologies, Inc. 

14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730
or 1-877-7RADPAD (1-877-772-3723)
Fax: 913-648-0131
Unknown

 

RADPAD-radiation-protection
RADPAD® Attends SIR 2017 Annual Scientific Meeting in Washington DC

RADPAD® Attends SIR 2017 Annual Scientific Meeting in Washington DC

Posted on March 24, 2017 by in Uncategorized with no comments

The Society of Interventional Radiology

SIR is a national organization of physicians, scientists and allied health professionals dedicated to improving public health through disease management and minimally invasive, image-guided therapeutic interventions.

SIRBanner2017-1


RADPAD at SIR 2017 

RADPAD-radiation-protectionD2A089EF-1A2C-41B3-B37E-930F888F1E92

 

Goals of the SIR 2017 Annual Scientific Meeting

It is SIR’s goal to promote the high-quality practice of interventional radiology through this and other educational programs. Meeting attendees will receive the latest information in basic and clinical research; experience techniques and technologies utilized by interventional radiologists around the world; see the latest equipment used in IR; and discuss social, political and economic issues important to the IR community.

 

SIR 2017 ANNUAL SCIENTIFIC MEETING OBJECTIVES

At the end of this meeting the learner should be able to:

1. Demonstrate the high-quality practice of interventional radiology in a team environment

2. Illustrate the latest information regarding basic and clinical research in diseases, including techniques and technologies integral to the practice of interventional radiology

3. Evaluate the latest equipment developed for interventional radiology procedures

4. Discuss societal, political and economic issues of importance to the interventional radiology community

 

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730
or 1-877-7RADPAD (1-877-772-3723)Fax: 913-648-0131

Email: info@radpad.com

Follow RADPAD® on Facebook
Unknown

WIT Wins Business Award: 25 Under 25®

Posted on February 10, 2017 by in Other Stories with no comments

Worldwide Innovations & Technologies, Inc. Has Won the 25 Under 25® Award

2016AwardsLookingDown_25U25

“Small businesses are a powerful, but often overlooked force in Kansas City,” said Kelly Scanlon, CEO of Thinking Bigger Business Media and the creator of 25 Under 25®.

“Together, these companies employ thousands upon thousands of people, deliver innovative products and services, and help support our government, schools, nonprofits and other public resources. Of course, most of our winners are too humble and too busy to brag about their contributions. But it’s a story that needs to be told. The 25 Under 25® Awards are proud to celebrate the important service of small businesses.”

 

About the 25 Under 25® Awards

As part of its 10-year anniversary celebration in 2002, Thinking Bigger Business Media Inc. launched the annual 25 Under 25® Awards to recognize 25 outstanding Kansas City businesses with under 25 employees.

Until the 25 Under 25® Awards, no formal recognition program existed in the Kansas City area that specifically targeted businesses with fewer than 25 employees. Yet this segment of business comprises the largest number of companies both locally and nationally, with roughly 83 percent of Kansas City area and 86 percent of businesses nationwide employing 19 or fewer employees.

With the establishment of the 25 Under 25® Awards program, small businesses are being recognized for the significant role they play in the Kansas City economy. The 25 Under 25® Awards program is not just about honoring individual businesses—it’s also about opening the public’s eyes to the economic, social and community impact of small businesses.

 

Honorees

December 7, 2016

Thinking Bigger Business Media is proud to announce the honorees of the 16th annual 25 Under 25® Awards—a group that represents the best of Kansas City’s small business community.

The awards are presented to 25 local businesses with fewer than 25 employees. An independent panel of judges consisting of area business leaders chooses the winning companies. Nearly 1,500 nominations were submitted. This year’s honorees include:

 

More info on the awards and the award reception here: https://ithinkbigger.com/events/25-under-25/

WORLDWIDE INNOVATIONS & TECHNOLOGIES, INC. (WIT)
14740 W 101st Terrace
Lenexa, KS 66215
Phone: 913-648-3730
or 1-877-7RADPAD (1-877-772-3723)

Fax: 913-648-0131

Email: info@radpad.com

Follow RADPAD® on Facebook
Unknown